Under the terms of the collaboration agreement, which is non-exclusive to both parties, NEC will provide funding for a Phase I clinical trial.
NEC and Vaximm will co-develop personalized cancer vaccines using NEC's cutting-edge artificial intelligence technology, which is utilized in its Neoantigen Prediction System, and Vaximm's proprietary T-cell immunotherapy technology.
The vaccines are planned to be evaluated in a Phase I clinical trial in various solid tumors.
Vaximm will be responsible for conducting the clinical trial, which is expected to be initiated in 2020.
NEC has the option for development and commercialisation rights to the program worldwide, except for China and other Asian territories outside of Japan.
NEC's neoantigen prediction utilises its proprietary AI which is combined with NEC OncoImmunity AS's bioinformatics pipelines making it the leading neoantigen prediction system in the field.
NEC evaluates candidate neoantigens, which allows it to effectively prioritise numerous candidate neoantigens identified in a single patient.
Aptagen awarded contract for developing parasitic disease diagnostic
Wave Neuroscience acquires brain treatment technology assets from NBRL
US FDA grants breakthrough therapy status to Bristol-Myers Squibb's Orencia
Gatehouse Bio forms collaboration with AstraZeneca
Alzheimer's, Parkinson's Collaboration of Mission and AbbVie Reaches Milestone
FDA Advisory Committee Will Review Reblozyl for Use in Patients with Myelodysplastic Syndromes